Skip to main content
Premium Trial:

Request an Annual Quote

Advinus to Use Corning's Epic Technology in India

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Indian therapeutics and drug development services firm Advinus Therapeutics will collaborate with Corning to offer Corning's Epic label-free detection services in India.

Under the agreement, Pune-based Advinus will use the Epic technology in its drug discovery capabilities and to provide assay development and screening services in India and abroad. Financial and other terms were not disclosed.

The Corning detection technology is used to identify targets, pathways, and interactions, providing data for use in drug development.

"This collaboration highlights the growing adoption of label-free technology and the biological insights it enables in drug discovery research," Ron Verkleeren, director of advanced life sciences for Corning, said in a statement. "We believe this is an important step forward in making our Epic technology more accessible to life science researchers worldwide."

Advinus offers end-to-end development services, is developing its own drug candidates, and in its center in Bangalore provides pre-clinical and early clinical drug development services.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.